Aberrations in Smo function are implicated in a variety of diseases, particularly cancers. Basal cell carcinoma (BCC) is a type of skin cancer that often involves mutations in the Hedgehog pathway, leading to constitutive activation of Smo. Additionally, Smo inhibitors like Vismodegib have been developed and are used as targeted therapies for treating cancers with aberrant Hedgehog signaling.
